Skip to content
Gennex Laboratories logo

Gennex Laboratories

531739 BSE
Price unavailable

Gennex Laboratories (GENNEX) share price was ₹9.10 at the 28 Oct 2026 close; market capitalisation ₹221 Cr; P/E (TTM) 11.97; sector Healthcare. The share price fell 46.5% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue rose 16.6% year on year to ₹39.84 Cr and net profit fell 6.8% year on year to ₹4.67 Cr (compared with Jun 2025). Promoters held 23.63% of Gennex Laboratories in Sep 2026, unchanged from Jun 2026. Its Tapetide Score is 49/100 (Average) as of 28 Oct 2026.

Close 28 Oct 2026 ₹9.10 −7.43 −44.95% 1Y

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare
Market Cap
₹221 Cr
P/E (TTM)
11.97
EBITDA
₹30.70 Cr
Return on Equity
9.01%
Debt to Equity
0.16
Book Value
₹9.16
EPS (TTM)
₹0.76
52W High
₹16.99
52W Low
₹7.05

Price-based figures as of 28 Oct 2026, 15:30 IST · EPS basis: Consolidated · TTM

Peer Comparison

Healthcare › Pharmaceuticals

Sun Pharma
₹1,766.1035.034,23,747 Cr5.070.91%13.79%17.94%61,848 Cr12,117 Cr
Divis Laboratories
₹9,626.0087.372,55,540 Cr15.250.32%15.32%18.96%11,682 Cr2,925 Cr
Torrent Pharmaceuticals
₹4,596.1072.151,74,821 Cr9.510.82%12.16%9.06%17,058 Cr2,156 Cr
Laurus Labs
₹2,183.80107.901,17,993 Cr22.260.09%16.38%19.67%7,323 Cr1,090 Cr
Zydus Life Science
₹1,180.5026.271,17,755 Cr4.340.09%16.99%19.24%28,515 Cr4,593 Cr
Dr Reddys Laboratories
₹1,340.8034.731,11,914 Cr2.880.61%10.87%13.94%34,247 Cr3,184 Cr
Cipla
₹1,370.9032.841,10,749 Cr3.130.96%11.21%14.88%28,589 Cr3,356 Cr
Gennex Laboratories (this company)
—11.97221 Cr0.990.00%9.01%9.93%182 Cr21 Cr
Median 8 companies₹1,766.1034.881,17,874 Cr4.710.47%12.98%16.41%22,787 Cr3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

49 Average
Overall score

Data confidence 100/100

Category scores

Quality Poor 33
Returns, margins, earnings quality 22% weight
Valuation Good 56
Cheap vs sector & own history 24% weight
Growth Strong 71
Sales & profit trajectory 9% weight
Financial Health Good 58
Solvency, leverage, coverage 9% weight
Momentum Poor 34
Trend strength, vol-adjusted 12% weight
Ownership Average 50
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

2
  • Stock is trading at 1.08 times its book value
  • Company has delivered good profit growth of 37.9% CAGR over last 5 years

Weaknesses

5
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Promoter holding is low: 23.6%
  • Tax rate seems low
  • Company has a low return on equity of 10.3% over last 3 years.
  • Debtor days have increased from 68.2 to 92.0 days.

Technical Indicators

Oscillators

Neutral

Bearish
2
Neutral
5
Bullish
2

Overall

Bearish

Bearish
10
Neutral
5
Bullish
4

Moving Averages

Bearish

Bearish
8
Neutral
0
Bullish
2

Growth Rate

Revenue Growth
22.05% lower than 3Y

change over 1 year

Net Income Growth
16.02% lower than 3Y

change over 1 year

Cash Flow Change
-566%

change over 1 year

EBITDA Margin Change
-7.38%

change over 1 year Operating margin 10.99% · Jun 2026

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
16.52
18.18
21.39
35.52
28.32
33.38
40.01
40.33
34.18
39.3
42.96
60.96
39.84
Expenses
11.42
12.41
16.59
29.26
24.1
25.92
32.86
38.31
29.11
31.74
34.39
55.07
35.46
Operating Profit
5.1
5.77
4.8
6.26
4.22
7.46
7.15
2.02
5.07
7.56
8.57
5.89
4.38
OPM %
30.87%
31.74%
22.44%
17.62%
14.9%
22.35%
17.87%
5.01%
14.83%
19.24%
19.95%
9.66%
10.99%
Other Income
0
0
0
0
2.47
0
0
3.68
2.28
0
-0.3
1.02
2.01
Interest
0.73
0.78
0.83
0.73
0.73
0.22
0.84
1.2
0.98
1.03
1.11
1.08
0.57
Depreciation
0.65
1.03
0.45
0.23
0.45
1.11
0.5
0.54
0.5
0.47
0.52
1.16
0.9
PBT
3.72
3.96
3.52
5.3
5.51
6.13
5.81
3.96
5.87
6.06
6.64
4.67
4.92
Tax %
23.39%
22.47%
21.31%
15.28%
15.43%
12.23%
12.91%
22.22%
14.48%
9.08%
9.79%
4.5%
5.08%
Net Profit
2.85
3.07
2.76
4.5
4.66
5.38
5.06
3.07
5.01
5.51
6
4.46
4.67
EPS (₹)
0.16
0.17
0.15
0.2
0.19
0.21
0.2
0.1
0.2
0.21
0.22
0.15
0.18
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
42
44
56
56
60
61
66
87
138
173
183
Expenses
37
42
52
52
53
56
61
70
121
150
157
Operating Profit
5
2
4
3
7
5
5
17
17
22
26
OPM %
11%
5%
7%
6%
11%
9%
7%
20%
12%
13%
14%
Other Income
0
1
1
1
0
1
4
5
10
8
3
Interest
1
1
1
1
1
1
1
3
4
4
4
Depreciation
1
1
1
1
1
1
1
2
2
3
3
PBT
3
1
3
3
5
5
6
16
21
23
22
Tax %
13%
42%
26%
27%
20%
23%
23%
20%
15%
10%
—
Net Profit
3
1
2
2
4
4
5
13
18
21
21
EPS (₹)
0.14
0.04
0.12
0.1
0.21
0.21
0.28
0.58
0.8
0.86
0.76
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
13
13
13
13
13
13
18
23
23
24
Reserves
18
19
21
23
27
31
62
148
164
198
Borrowings
4
2
5
5
7
10
1
6
10
36
Other Liabilities
14
16
13
16
12
14
51
54
59
90
Total Liabilities
49
50
52
57
59
68
132
230
256
349
Fixed Assets
16
16
16
15
14
14
74
56
60
61
CWIP
0
0
0
0
0
0
0
2
5
13
Investments
7
7
7
7
7
7
0
0
0
0
Other Assets
26
28
29
35
38
48
59
172
191
275
Total Assets
49
50
52
57
59
68
132
230
256
349
Figures in ₹ Crores

Cash Flow

Particulars Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
0
3
2
-2
-1
12
24
-47
-10
-64
Investing
-1
-1
-1
0
0
-2
-38
19
3
-5
Financing
1
-2
1
0
2
-2
21
74
2
65
Net Cash Flow
0
0
2
-2
0
8
6
46
-5
-3
Free Cash Flow
-1
2
1
-2
-2
10
-16
-31
-15
-76
CFO/OP
13
190
55
-52
1
242
505
-274
-39
-274
Figures in ₹ Crores

Ratios

Particulars Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
90
87
68
41
55
67
52
75
37
92
Inventory Days
43
31
57
78
50
72
139
184
133
152
Days Payable
139
161
88
86
59
72
63
111
49
57
Cash Conversion Cycle
-7
-43
38
34
46
67
129
148
122
187
Working Capital Days
74
75
56
87
108
87
23
255
214
295
ROCE %
—
6%
11%
8%
14%
12%
11%
14%
13%
12%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Gennex Laboratories insights

62 extracted metrics + investor summaries across FY10–FY27.

Shareholding Pattern

Public56.30%Others20.07%Promot.23.63%As ofSep 2026
21.77% of promoter holding pledged as of 14 Oct 2026

Documents

Frequently Asked Questions about Gennex Laboratories

What does Gennex Laboratories Ltd do?
Incorporated in 1995, Gennex Laboratories Ltd manufactures Bulk Drugs and Intermediaries[1]
Where is Gennex Laboratories Ltd (GENNEX) listed?
Gennex Laboratories Ltd trades under code 531739 on the BSE.
Which sector does Gennex Laboratories Ltd belong to?
Gennex Laboratories Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Gennex Laboratories Ltd?
Gennex Laboratories Ltd has a market capitalisation of ₹221.06 Cr as of 28 Oct 2026, which places it in the Small Cap band.
What is the PE ratio of Gennex Laboratories Ltd?
Gennex Laboratories Ltd trades at a PE ratio of 11.97 as of 28 Oct 2026, on earnings per share of ₹0.76, against a book value of ₹9.16 per share.
What is the 52-week high and low of Gennex Laboratories Ltd?
Over the last 52 weeks Gennex Laboratories Ltd has traded between ₹7.05 and ₹16.99 as of 28 Oct 2026.
What is the Return on Equity (ROE) of Gennex Laboratories Ltd?
Gennex Laboratories Ltd reported a return on equity of 9.01%. Its debt-to-equity ratio is 0.16.

Company Information

Incorporated in 1995, Gennex Laboratories Ltd manufactures Bulk Drugs and Intermediaries[1]

Website gennexlab.com
Face Value ₹ 1
Shares Outstanding 24,29,21,348

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/531739.md for Gennex Laboratories Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month